Milligan Sandra
- SEC CIK
- 0001859810
No open-market purchases or sales filed in the past year.
Current role at each company
- GOSS Gossamer Bio, Inc.Directoras of Sep 25, 2026
- SYRE Spyre Therapeutics, Inc.Directoras of May 29, 2026
- AWHL Aspira Women's Health Inc.Interim CEOas of Jan 29, 2025
- OGN Organon & Co.Head of Research & Developmentas of May 8, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Milligan Sandra as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
GOSS Gossamer Bio, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2023 (view filing) | Nov 15 | 2 days | Milligan SandraDirector | PPurchase | +32.0K | $0.79 | +$25.3K | New position32.0K after | |
| Aug 20, 2025 (view filing) | Aug 19 | 1 day | Milligan SandraDirector | PPurchase | +26.1K | $1.92 | +$50.0K | +81.4%58.0K after |